News

Eli Lilly's Omvoh wins Health Canada approval for Crohn’s disease
Eli Lilly (NYSE:LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company ...
Health Canada Approves Lilly's Omvoh® (mirikizumab) for Crohn's Disease; New Citrate-Free Formulation
Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will ...
pharmaphorum7d
NICE backs new drugs for Crohn's disease, lymphoma
Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...
Longview News-Journal6mon
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease ...
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical ...
WKRG1y
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class ...
Lilly's first approved treatment for a type of inflammatory bowel disease INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug ...
Monthly Prescribing Reference1y
Omvoh, a Novel Treatment for Ulcerative Colitis, Receives FDA ... - MPR
Omvoh is an interleukin-23 antagonist. Omvoh is supplied in a single-dose vial containing 300mg/15mL solution for IV infusion and as a single-dose prefilled pen containing 100mg/mL solution for SC ...
Nasdaq1y
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in ... - Nasdaq
About Omvoh™Omvoh (mirikizumab-mrkz) is an interleukin-23p19 antagonist indicated for the treatment of moderately to severely active ulcerative colitis in adults.